BRISBANE, Calif.--(BUSINESS WIRE)-- Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced the presentation of preclinical data from its lead COBRA™ programs, MVC-101 and MVC-280, at the 2^nd Annual Cell Engager Summit taking place virtually from August 18 to August 20, 2020.

Chad May Ph.D., Senior Vice President, Research & Development, Maverick Therapeutics, will reveal new preclinical data characterizing the conditional and potent activity of its second program candidate, MVC-280, a COBRA that targets B7H3, during a presentation titled “Protease Dependent COBRA^TM Activity Regresses Established Tumors in Mice.” The preclinical data demonstrate that MVC-280 regresses established solid tumors in mice and increases tolerability relative to inherently active T cell engagers. Dr. May is also scheduled to participate in a panel discussion on the opportunities within the tumor microenvironment to widen the therapeutic index.

“The preclinical data from MVC-280 are extremely encouraging and highlight the therapeutic potential for COBRAs to pursue more broadly expressed and validated targets,” said Chad May, Ph.D., Senior Vice President, Research & Development, Maverick Therapeutics. “The binding kinetics of the MVC-280 COBRA also gave us a unique opportunity to assess tolerability and efficacy within the same in vivo model and enabled the calculation of a therapeutic index, which we consider to be 30 to 100x greater than that of an inherently active T cell engager.”

Highlights of the presentation include:

• MVC-101 regressed established solid tumors expressing EGFR in mice
• MVC-280 regressed established solid tumors expressing B7H3 in mice
• Half-life extended COBRAs are cleared more rapidly after proteolytic activation
• Regression of established solid tumors is dependent on tumor mediated linker cleavage and COBRA activation
• The COBRA design increases the therapeutic window

Presentation Schedule

Panel Discussion:

• Title: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity
• Date & Time: Wednesday, August 19, 2020 at 11:30AM ET

Presentation:

• Title: Protease Dependent COBRA™ Activity Regresses Established Tumors in Mice
• Session: Analyzing Tumor Target Selection to Maximize Efficacy Whilst Minimizing Toxicity
• Date & Time: Thursday, August 20, 2020 at 9:30AM ET

About the COBRA™ Platform

Maverick Therapeutics’ COBRA™ platform is the most mature conditionally active bispecific T cell engaging platform designed to safely target a broad range of solid tumors with highly specific and potent activity while limiting on-target toxicities in normal tissues. By nature of its highly innovative design, the COBRA platform reflects a novel approach to T cell engaging immunotherapies where T cell activation and resulting cell killing only take place where it is needed – in tumors. This unique design delivers the long sought trifecta in cancer care; high specificity, high potency and reduced toxicity.

About MVC-101

Maverick Therapeutics’ lead program candidate, MVC-101, is a proprietary COBRA™ molecule designed to target the Epidermal Growth Factor Receptor (EGFR), a protein expressed on both malignant and healthy tissues. MVC-101 regressed established human tumors in several preclinical models. Exposures of MVC-101 at efficacious relative to tolerated doses in safety studies demonstrates an increased therapeutic index compared to standard T cell engagers. MVC-101 is designed to be a universal solution for patients with EGFR expressing solid tumor cancers. EGFR is expressed on a wide range of solid tumor cancers, including but not limited to colorectal, head & neck, renal, pancreatic, cervical and non-small cell lung cancers. Maverick expects to initiate a Phase 1/2, Open Label, Dose Escalation Study of MVC-101 in Q1 2021.

About MVC-280

Maverick Therapeutics’ second program candidate, MVC-280, is a proprietary COBRA™ molecule designed to target B7H3 (CD276). B7H3 is expressed in a broad range of malignant and healthy tissues, similar to EGFR. MVC-280 regressed established tumors in several preclinical models. It is cross-reactive to its target protein expressed on mouse tissues, creating an opportunity to measure both efficacy and relative safety in the same preclinical model and use that data to calculate a therapeutic index. MVC-280 is designed to be a universal solution for patients with B7H3 expressing solid tumor cancers. B7H3 is expressed on a wide range of solid tumor cancers, including but not limited to prostate, renal, triple negative breast, head & neck, ovarian and urothelial cancers. Maverick expects to initiate a Phase 1/2, Open Label, Dose Escalation Study of MVC-280 in H2 2021.

About Maverick Therapeutics

Maverick Therapeutics is establishing itself as the leader in the race to apply T cell therapy to solid tumor cancers by focusing deep integrated expertise in drug development to design and deliver a pioneering immunotherapy platform. Maverick’s highly innovative COBRA™ therapeutic platform is the most mature, conditionally active bispecific T cell engaging platform designed to eliminate solid tumors. With COBRA, T cell activation and resulting cell killing only take place where it is needed – in tumors. This unique design delivers the long sought trifecta in cancer care; high specificity, high potency and reduced toxicity. Founded in 2016, Maverick is led by a team of leading experts in protein engineering and T cell therapeutic research and development. In early 2017, Maverick announced $125 million of committed funding from Takeda Pharmaceuticals (“Takeda”), MPM BioVentures 2014 and MPM Capital’s UBS Oncology Impact Fund. For further information, please visit www.mavericktx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005125/en/